Cancerr

The U.S. Food and Drug Administration approved Wednesday Gilead Sciences, Inc. (NASDAQ: GILD)'s therapy for the treatment of non-Hodgkin's Lymphoma (NHL) called YESCARTA. The announcement helped boost Gilead's stock higher by more than 1 percent Thursday, yet some on Wall Street aren't ready to...